Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
View through CrossRef
The loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target. Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα. Malignant lymphocytes of mycosis fungoides and Sézary syndrome express CD47 highly, thus, being ideal candidates for targeted anti-CD47 therapies. The classes of current anti-CD47-SIRPα therapeutic molecules present in a large variety and include monoclonal antibodies against CD47 and SIRPα, bioengineered SIRPα proteins, miRNAs, and bispecific antibodies. We provided a detailed analysis of all available investigational drugs in a contest of cutaneous T-cell lymphoma. A combination of blockade of the CD47-SIRPα axis and secondary targets in the tumor microenvironment (TME) may improve the clinical efficacy of current immunotherapeutic approaches. We evaluated the possible combination and outlined the most promising one.
Title: Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
Description:
The loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target.
Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα.
Malignant lymphocytes of mycosis fungoides and Sézary syndrome express CD47 highly, thus, being ideal candidates for targeted anti-CD47 therapies.
The classes of current anti-CD47-SIRPα therapeutic molecules present in a large variety and include monoclonal antibodies against CD47 and SIRPα, bioengineered SIRPα proteins, miRNAs, and bispecific antibodies.
We provided a detailed analysis of all available investigational drugs in a contest of cutaneous T-cell lymphoma.
A combination of blockade of the CD47-SIRPα axis and secondary targets in the tumor microenvironment (TME) may improve the clinical efficacy of current immunotherapeutic approaches.
We evaluated the possible combination and outlined the most promising one.
Related Results
Abstract 1645: Cell-based reporter bioassays for the development of Fc-functional and Fc-silent SIRPα/CD47 checkpoint inhibitors
Abstract 1645: Cell-based reporter bioassays for the development of Fc-functional and Fc-silent SIRPα/CD47 checkpoint inhibitors
Abstract
CD47, a membrane glycoprotein commonly overexpressed in human cancers, interacts with its cognate receptor SIRPα on myeloid cells to deliver a “don't eat me...
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract
Introduction
Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Exploring the Association between Lymphoma and Inflammatory Bowel Disease in an Inner-City Academic Institution
Exploring the Association between Lymphoma and Inflammatory Bowel Disease in an Inner-City Academic Institution
Introduction:
The incidence of lymphoma has been increasing over the past several decades, with data showing an estimated annual percentage change of 0.56%. There...
Abstract 496: Humanized SIRPA and double humanized SIRPA/CD47 B-NDG mouse models are promising tools for anti-SIRPα antibody in vivo efficacy studies
Abstract 496: Humanized SIRPA and double humanized SIRPA/CD47 B-NDG mouse models are promising tools for anti-SIRPα antibody in vivo efficacy studies
Abstract
The CD47/Signal regulatory protein α (SIRPα) axis regulates myeloid cell activation and functions as a crucial myeloid specific immune checkpoint. CD47 is h...
Abstract 725: Listeria-inspired phagosome escape drives STING responses to CD47 blockade
Abstract 725: Listeria-inspired phagosome escape drives STING responses to CD47 blockade
Abstract
Purpose: Through phagocytosis, antigen-presenting cells (APCs) engulf and neutralize malignant cells. However, engulfed tumor cells are destroyed in phagol...
MO244CD47 BLOCKADE AMELIORATES AUTOIMMUNE VASCULITIS VIA THE EFFEROCYTOSIS OF NEUTROPHIL EXTRACELLULAR TRAPS*
MO244CD47 BLOCKADE AMELIORATES AUTOIMMUNE VASCULITIS VIA THE EFFEROCYTOSIS OF NEUTROPHIL EXTRACELLULAR TRAPS*
Abstract
Background and Aims
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by systemi...
Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
Background: Cancer cells escape macrophage phagocytosis by expressing the CD47 integrin-associated protein that binds to the SIRPα ligand (signal regulatory protein alpha) expresse...
Co-targeting CD47 and VEGF Elicited Potent Antitumor Effects in Gastric Cancer
Co-targeting CD47 and VEGF Elicited Potent Antitumor Effects in Gastric Cancer
Abstract
Background
CD47, serving as an intrinsic immune checkpoint, has demonstrated efficacy as an antitumor target in hematologic malignancies. Nevertheless, the clinic...